Remogliflozin etabonate is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Remogliflozin etabonate was shown to enhance urinary glucose excretion in rodents and humans. Remogliflozin etabonate is a pro-drug of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT), which are responsible for glucose reabsorption in the kidney. Remogliflozin is selective for sodium-glucose transport proteins 2 (SGLT2). Various Remogliflozin etabonate related compounds or reference standards, listed on this page are needed in pharmaceutical research at the time to product development, ANDA filing or during production to study quality, stability, and genotoxicity study of Remogliflozin etabonate related products.

 

Synthink is a most trusted source of Remogliflozin etabonate Degradation Impurities, Remogliflozin etabonate Genotoxic impurity, Remogliflozin etabonate Process Impurities, USP related compounds, Remogliflozin etabonate Nitrosamine impurity, N-Nitroso impurity etc. which are listed on this page.

Filter